Medivir Q2 2025: Awaiting Phase IIb - Redeye
Bildkälla: Stockfoto

Medivir Q2 2025: Awaiting Phase IIb - Redeye

Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has made further progress and is essentially ready for the planned pivotal phase II study in liver cancer. The only thing missing is funding.

Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has made further progress and is essentially ready for the planned pivotal phase II study in liver cancer. The only thing missing is funding.
Börsvärldens nyhetsbrev